$IPSC

Russotti Gregory sold $6K of IPSC

Russotti Gregory (See Remarks) sold 2,584 shares of Century Therapeutics, Inc. (IPSC) at $2.23 on 2026-06-12.

Original reporting
SEC EDGAR · Russotti Gregory
Published Jun 15, 2026, 11:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IPSC
Neutral
medium confidence
Mentioned
$IPSC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

An officer/direct insider sold shares in an open-market transaction; without additional company news, the trading implication is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article lacks context on total insider holdings, prior sale cadence, and whether other insiders/10b5-1 plans are active—these can materially change interpretation.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15 for a 2026-06-12 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCNeutralMedium confidence
Context

SEC Form 4 shows officer Russotti Gregory sold 2,584 shares of Century Therapeutics (IPSC) on 2026-06-12 at $2.2320.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is a small, single-sale event with no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-through provided; this is company-specific ownership activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • Century Therapeutics, Inc.

    Subject of the SEC Form 4 insider transaction disclosure (IPSC).

  • Russotti Gregory

    Officer who executed the open-market sale of 2,584 shares.

Related articles

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa